ANI Pharmaceuticals (ANIP)

[Just the facts maam]

I think you are right about the method of delivery to patients. The retrospective study is designed to create a scale to tell patient the odds that they will experience dementia, and secondary analyses such as depression and anxiety.

Primary Outcome Measures :
Association between germline genetic predictors (single nucleotide variants) of lower testosterone levels and dementia risk [ Time Frame: Up to 2 years ]
Will utilize genetic variants associated with testosterone levels at genome-wide statistical significance thresholds (P < 5 x 10-8) in published meta-analyses. Will additionally conduct a genome-wide association study with testosterone values in the UK Biobank. Will construct a weighted genetic risk score based on the strength of each variant's association with testosterone levels in published datasets. The results of the weighted method will be scaled per standard deviation (SD) of testosterone levels so that effect sizes represent the odds ratio of the outcome (e.g. dementia) per genetically predicted SD decrease in testosterone levels. Will also utilize risk scores with less stringent significance thresholds in secondary analyses (P < 5 x 10-6).

M.D Anderson has 8 trials where Electronic Health Record Review is included in the Intervention/Treatment. All the other studies are cancer related and the one with the most participants is 2,000, electronic review was recently added to a study starting in 2007.

700,000 participants is a huge population and should carry a lot of weight when the results are published.

iElectronic Health Record Review

I agree Abbott is also well positioned.